D rug therapy of lipid abnormalities in children and adolescents has been surrounded with controversy. Much of the debate is about the evidence that intervening in asymptomatic youth will reduce disease morbidity or mortality in adulthood. There is also particular concern that the increasing prevalence of lipid abnormalities associated with the epidemic of pediatric obesity will lead to a generation of children taking long-term medication for lifestylerelated issues. The Writing Group, therefore, sought to examine the current state of evidence and guidelines and to provide clarifications and modifications, which are detailed in their Scientific Statement. 1
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Imperative for Intervention
A substantial body of evidence now exists to assert that the atherosclerotic process begins in childhood and is associated with the recognized cardiovascular risk factors. Pathologic studies, such as the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study, have shown strong associations with the extent of early atherosclerotic lesions and levels of risk factors, including lipid abnormalities. An important observation from pathology studies has been the geometric association between increasing number of risk factors and the extent of lesions, which has important implications in view of the increasing prevalence of risk factor clustering associated with obesity and the metabolic syndrome. Populationbased studies, such as the Bogalusa Heart Study and the Muscatine Study, find increasing trends in adiposity and associated risk factors in youth, and that both risk factors and obesity track into adulthood. These studies demonstrate associations between lipid abnormalities and noninvasively measured markers of early atherosclerosis. Recent clinical trials have shown that effective lowering of LDL-cholesterol levels in youth with familial or severe hypercholesterolemia is associated with improvement and even regression of early markers. 2, 3 This evidence informs the imperative for the identification and effective treatment of children and adolescents with high-risk lipid abnormalities.
Clinical Studies of Drug Therapy in Children
There have been several well-designed clinical trials that have explored the short-term efficacy and safety of lipidlowering drug therapy in children with familial hypercholesterolemia or severe hypercholesterolemia ( Table 1 ). These studies have primarily used existing guidelines to define inclusion and exclusion criteria, often included a doubleblind, placebo-controlled, randomized phase, and were of 1 or 2 years duration. The focus has been primarily on the bile-acid-binding resins and, more recently, the statins. These studies find similar safety and efficacy as do studies in adults. The bile-acid-binding resins have been associated with poor tolerability and compliance in children and with limited effectiveness in achieving lipid-lowering targets. Based on these findings, statins are now recommended as first-line therapy for those children and adolescents who meet criteria for drug therapy to lower LDL-cholesterol levels. Initiation, monitoring, titration and maintenance are similar for adults. However, statin use in the pediatric population requires particular attention to ongoing monitoring of growth, maturation and development, counseling and assurance of appropriate contraception in females, and drug interactions. Concomitant maintenance of therapeutic healthy lifestyle behaviors and the prevention of obesity are also essential. Further studies are needed to document long-term compliance, safety and effectiveness, as well as the clinical impact on the atherosclerotic disease process. Rigorous pediatric studies should be performed for all drugs used to treat lipid abnormalities.
Existing Guidelines and Challenges
Existing guidelines primarily derive from an Expert Panel convened by the National Cholesterol Education Program, which published their discussion and recommendations in 1992. 4 They advocated a population-based approach aimed at downward shifting of cholesterol levels primarily through adoption of a fat-reduced and cholesterolrestricted prudent diet. They also advocated a screening algorithm aimed at identifying individuals with very high levels of LDL-cholesterol. Screening was initiated on the basis of family history of premature atherosclerotic cardiovascular disease or events or important hypercholesterolemia. Based on LDL-cholesterol levels, recommendations were made regarding subsequent monitoring, further investigation, and implementation of a more rigorous dietary intervention. Selected individuals with persistent and more extreme elevations of LDL-cholesterol would be eligible for consideration of drug therapy only after the age of 10 years (Table 2) . Bile-acid-binding resins were recommended as first-line therapy.
There have been several concerns and challenges regarding these guidelines, particularly in light of newer evidence. There has been increasing recognition of the limitations of screening based on family history, and the increasing prevalence of lipid abnormalities because of the pediatric obesity epidemic. The guidelines did not address racial, ethnic, age and gender-specific differences that might influence screening cut-point levels and differences in disease risk. As more evidence has accumulated there has been increased awareness of the interaction of lipid abnormalities with other risk factors and high-risk disease states; thus, there needs to be some flexibility and integration of the guidelines. 5 Ongoing experience with the recommended bile-acid-binding resins has been discouraging, whereas short-term clinical trials of the statins have shown excellent safety and efficacy, in addition to a positive effect on noninvasive measures of early atherosclerosis. 2,3
Current Modifications
Current modifications are provided in Table 2 . The major changes include an adjuvant focus on pediatric overweight and obesity, the recognition of statins as first-line drug therapy, and the incorporation of flexibility into initiation decisions based on the presence of other important risk factors and high-risk disease states.
Conclusions
Although a perfect chain of evidence may never exist to show that management of lipid abnormalities in youth leads to a subsequent reduction of cardiovascular disease, events and mortality in adults, several links in the chain are well established. This statement highlights those links and the evidence supporting them, and establishes the imperative and guidelines for treating children and adolescents with high-risk lipid abnormalities with safe and effective drug therapy. This table was previously published in Circulation. 1 
